

IOWA DEPARTMENT OF PUBLIC HEALTH
BUREAU OF RADIOLOGICAL HEALTH
LUCAS STATE OFFICE BUILDING
DES MOINES, IOWA 50319

August 2013

IDPH INFORMATION NOTICE 2013-04 Clarification of licensing requirements for the use of Radium-223 dichloride ($^{223}\text{RaCl}_2$)

ADDRESSEES

All material licensees that are authorized to perform therapeutic procedures using radiopharmaceuticals.

PURPOSE

The Iowa Department of Public Health (IDPH) is issuing this information notice (IN) to clarify the licensing requirements for the medical use of Radium-223 dichloride ($^{223}\text{RaCl}_2$) under Iowa Administrative Code (IAC) 641-41.2(37).

DESCRIPTION OF CIRCUMSTANCES

Since the issuance of IDPH Information Notice 2013-03, this office has received several questions and inquiries regarding the licensing for Radium-223 dichloride ($^{223}\text{RaCl}_2$) for medical use in Iowa.

DISCUSSION

Licensees authorized in accordance with IAC 641-41.2(37), "Use of unsealed by-product material for which a written directive is required" *with no restrictions* and Authorized Users trained in accordance with IAC 641-41.2(69), "Training for use of unsealed by-product material for which a written directive is required" who are listed on the specific radioactive materials license as an authorized user for IAC 641-41.2(37) *with no restrictions* are authorized for the medical use of $^{223}\text{RaCl}_2$. Any restrictions identified on a radioactive materials license for medical use of unsealed byproduct material under IAC 641-41.2(37) or restrictions on an authorized user would require an amendment to the radioactive materials license in order to be authorized for the medical use of $^{223}\text{RaCl}_2$

CONTACT

This Information Notice requires a written response. Any material licensee who is currently performing therapeutic procedures using Radium-223 dichloride and any material licensee wishing to perform these procedures must notify this office of the use or intent to use Radium-223 dichloride. This office will review the radioactive materials license for the licensee and make a determination whether or not the licensee is authorized for such procedures. IDPH will then inform the licensee, in writing, of the approval or disapproval for the use of Radium-223 dichloride.

Licensees must reply to this Information Notice no later than October 1, 2013, of either their current use of Radium-223 dichloride or intended use of the product.

If you have any questions about the information in this notice, please contact this office.



Melanie Rasmusson, Chief
Bureau of Radiological Health
515-281-3478
melanie.rasmusson@idph.iowa.gov